ASP Isotopes Announces CEO Paul Mann Will Become Executive Chairman And Take Temporary Medical Leave From His CEO Duties Starting October 1, 2025 And Appoints COO Robert Ainscow As Interim CEO While Mann Is On Leave

Author: Benzinga Newsdesk | September 29, 2025 07:14am

ASP Isotopes Inc. NASDAQ: ASPI ("ASP Isotopes" or the "Company"), an advanced materials company dedicated to the development of technology and processes for the production of isotopes for use in multiple industries, today announced that, effective October 1, 2025, Paul Mann, the founder, Chairman and Chief Executive Officer of ASP Isotopes, will become Executive Chairman of ASP Isotopes and will be taking a temporary leave of absence from his Chief Executive Officer duties for health reasons. In consultation with Mr. Mann, and effective October 1, 2025, ASP Isotopes' Board of Directors (the "Board") appointed Robert Ainscow, the Company's Chief Operating Officer, to serve as Interim Chief Executive Officer (principal executive officer), in addition to his current duties.

Posted In: ASPI